HER2 mutations and overexpression, while predominantly linked to breast cancer, are also present in other solid tumors, including lung and stomach cancers, where they exacerbate tumor aggressiveness and lead to inferior outcomes [13,36,37,38]. This evidence concerns the gene ERBB2 and neoplasm.